Acute kidney injury news

Restricted access

Two manufacturers reported on recent results in acute kidney injury (AKI) studies.

Biopharmaceutical company AM-Pharma, based in Bunnik, the Netherlands, announced that its phase II STOP-AKI study demonstrated a noteworthy reduction in mortality in a 28-day period. The company is focused on the development of recombinant human alkaline phosphatase (recAP) for the treatment of AKI, ulcerative colitis, and hypophosphatasia. Pfizer acquired a minority interest in AM-Pharma in May 2015 and may acquire the rest of the company through an option.

The 301-patient study compared a treatment group of sepsis patients with AKI with a similar group receiving placebo. Adding recAP

Save